Baxter (NYSE:BAX) said today it inked a partnership deal with the International Society of Nephrology looking to advance awareness and therapy for patients with chronic kidney disease, primarily in low and middle-income countries where the disease is growing the fastest.
In the collaborative partnership , Deerfield, Ill.-based Baxter and the ISN will look to support further therapy research and education about chronic kidney disease, while also looking to develop better care models at lower costs.
“ISN and Baxter’s collaboration aims to address the urgent and growing challenge kidney disease is causing healthcare systems in providing quality care to patients globally. Our organization is dedicated to connecting communities to collaborate on supporting greater access to care models that focus on how to improve prevention, diagnosis and treatment of kidney disease,” Dr. David Harris of Australia’s University of Sydney said in a prepared statement.
“It is Baxter’s goal to make renal care available to people in need, while driving better outcomes through new standards. Our partnership with ISN moves us closer to this goal by combining Baxter’s clinical and innovation expertise with ISN’s educational and research expertise in a truly transformative approach to increasing access to care worldwide,” Baxter renal care GM Laura Angelini said in a press release.
In March, Baxter said it that it closed the $153 million acquisition of hemostat and sealant assets from Mallinckrodt Pharmaceuticals (NYSE:MNK).
